Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple regimen of high- and low-dose radiotherapy plus immunotherapy in advanced solid tumors after failure of first-line therapy
ChiCTR2500114399Phase 2Not yet recruiting
- Sponsor
- Donghai County People's Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adalimumab in Nonhematologic neoplasms, sponsored by Donghai County People's Hospital. Primary endpoints: Objective response rate and Progression-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500114399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114399.